Business Description
Compare
Compare
Traded in other countries / regions
6IB.Germany01801.Hong KongIVBIY.USA IPO Date
2018-10-31Description
Innovent is a China-based biotechnology company that is developing drugs for a wide array of diseases, especially oncology therapeutics. Founded in 2011, it listed on the Hong Kong Stock Exchange in 2018. Its core asset is a PD-1 inhibitor called Tyvyt or sinitilimab. It also has a portfolio of three biosimilars of bevacizumab, rituximab, and adalimumab. Innovent has been adept global business development, having out-licensed Tyvyt to Eli Lilly and in-licensed innovative drugs from several partners.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.54 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.29 | |||||
| Debt-to-EBITDA | -0.98 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 5.17 | |||||
| Beneish M-Score | -0.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 382.4 | |||||
| 3-Year EBITDA Growth Rate | 50.6 | |||||
| 3-Year EPS without NRI Growth Rate | 48.7 | |||||
| 3-Year FCF Growth Rate | 10.2 | |||||
| 3-Year Book Growth Rate | 27.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 26.07 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.93 | |||||
| 9-Day RSI | 42.97 | |||||
| 14-Day RSI | 44.88 | |||||
| 6-1 Month Momentum % | 59.67 | |||||
| 12-1 Month Momentum % | 21.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.22 | |||||
| Quick Ratio | 2.79 | |||||
| Cash Ratio | 2.02 | |||||
| Days Inventory | 579.73 | |||||
| Days Sales Outstanding | 84.16 | |||||
| Days Payable | 104.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.2 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.94 | |||||
| Operating Margin % | -64.12 | |||||
| Net Margin % | -68.08 | |||||
| ROE % | -29.22 | |||||
| ROA % | -19.05 | |||||
| ROIC % | -43.1 | |||||
| ROC (Joel Greenblatt) % | -68.41 | |||||
| ROCE % | -22.3 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 10.26 | |||||
| PB Ratio | 5.01 | |||||
| Price-to-Tangible-Book | 5.49 | |||||
| EV-to-EBIT | -15.35 | |||||
| EV-to-Forward-EBIT | -17.96 | |||||
| EV-to-EBITDA | -16.69 | |||||
| EV-to-Forward-EBITDA | -20.1 | |||||
| EV-to-Revenue | 10.04 | |||||
| EV-to-Forward-Revenue | 7.16 | |||||
| EV-to-FCF | -12.22 | |||||
| Price-to-Net-Current-Asset-Value | 10.41 | |||||
| Price-to-Net-Cash | 104.05 | |||||
| Earnings Yield (Greenblatt) % | -6.51 |
How Innovent Biologics Inc (HKSE:01801) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 5,475.788 | ||
| EPS (TTM) (HK$) | -2.562 | ||
| Beta | 0.72 | ||
| Volatility % | 68.88 | ||
| 14-Day RSI | 44.88 | ||
| 14-Day ATR (HK$) | 2.388675 | ||
| 20-Day SMA (HK$) | 40.1225 | ||
| 12-1 Month Momentum % | 21.14 | ||
| 52-Week Range (HK$) | 18.06 - 47.95 | ||
| Shares Outstanding (Mil) | 1,534.32 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Innovent Biologics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Innovent Biologics Inc Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Innovent Biologics Inc Frequently Asked Questions
What is Innovent Biologics Inc(HKSE:01801)'s stock price today?
The current price of HKSE:01801 is HK$38.50. The 52 week high of HKSE:01801 is HK$47.95 and 52 week low is HK$18.06.
When is next earnings date of Innovent Biologics Inc(HKSE:01801)?
The next earnings date of Innovent Biologics Inc(HKSE:01801) is 2023-03-29 Est..
Does Innovent Biologics Inc(HKSE:01801) pay dividends? If so, how much?
Innovent Biologics Inc(HKSE:01801) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
